课题基金 / 基金详情

项目摘要

项目成果

LARS ECKMANN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Constant exposure to harmless food antigens requires that intestinal immune responses are normally biased towards tolerance and development of regulatory T cells, yet infections with intestinal pathogens induce effector T cells and aggressive antimicrobial immune defenses. The mechanisms underlying the differential recognition of harmless food antigens and threatening microbial antigens, and the corresponding immune decision processes, are central to the understanding of mucosal immunity and its exploitation for preventive and therapeutic medical strategies such as vaccination and immunotherapy. The "reprogramming" from regulatory to effector T cells typically occurs in the context of inflammation initiated by innate recognition of conserved microbial molecules through Toll-like receptors and other innate sensors. However, the host mounts effective immune responses to certain enteric pathogens without mucosal inflammation. An important pathogen of this category is the protozoan parasite, Giardia, which is a major cause of diarrheal disease woridwide. It colonizes the lumen and epithelial surface of the small intestine, and activates effective mucosal immune defenses, but does not invade the mucosa or cause significant inflammation. The overall goal of our studies is to exploit Giardia as a model to elucidate the mechanisms that govern immune decisions in the intestinal tract in the absence of inflammation. The studies have the following Specific Aims: Aim 1. To determine the mechanisms of dendritic cell-dependent immune defense against Giardia. Aim 2. To define the mechanisms of G/ard/a-triggered colitis in suseptible hosts. Aim 3. To investigate the function of IL-17 in giardiasis. The proposed studies will generate important new insights into the immune processes and decisions that take place in the intestinal tract at the interface of local resident cells, innate immune cells, and professional immune cells of the T and B cell lineages in the context of a protozoan infection. Furthermore, the work will provide a basis for the rational design of improved strategies for treating and preventing giardiasis and possibly infection with other clinically important luminal pathogens. RELEVANCE (See instructions): Giardia lamblia, a NIAID/CDC Category B priority pathogen, is a major cause of diarrheal disease woridwide and the leading cause of waterborne disease in the United States. Giardia is highly contagious and a credible threat to public water supplies and health. New insights into immune defenses against the parasite will be important for designing improved treatment and prevention strategies against giardiasis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis
Proteasome inhibitors against mucosal protozoan pathogens
Proteasome inhibitors against mucosal protozoan pathogens
Membrane-cloaked nanoparticles as mucosal vaccines against giardiasis
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2022
  • 负责人:
    王亚伟
  • 依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究